Total current assets Total assets Related and Nonrelated Parties [Axis] Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balances Balances Total liabilities, convertible preferred stock and stockholders’ equity Statement of Income Location, Balance [Axis] Total operating expenses Loss from operations Total other income (expense), net Net loss and comprehensive loss Net loss Loss Allocation (in Dollars) Balances (in Shares) Balances (in Shares) Preferred Stock Issued and Outstanding Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net increase in cash and cash equivalents Cash at beginning of period Cash and cash equivalents at end of period Nature of the Business and Basis of Presentation [Abstract] Summary of Significant Accounting Policies [Abstract] Long-Lived Tangible Asset [Axis] Statistical Measurement [Axis] Reverse Recapitalization and Pre-Closing Financing [Abstract] Net assets acquired Fair Value Measurements [Abstract] Cash and Cash Equivalents [Axis] Fair Value Hierarchy and NAV [Axis] Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Accrued Expenses and Other Current Liabilities [Abstract] Total Accrued expenses and other current liabilities Note Payable with Related Party [Abstract] Convertible Preferred Stock and Stockholders’ Equity [Abstract] Plan Name [Axis] Stock-Based Compensation [Abstract] Debt Instrument [Axis] Schedule of Stock Option Activity [Abstract] Number of Stock Options, Beginning Balance Number of Stock Options, Ending Balance Outstanding and issued stock options Weighted Average Exercise Price Per Share, Beginning Balance Weighted Average Exercise Price Per Share, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Number of RSAs, Unvested balance Number of RSAs, Unvested balance Weighted Average Grant Date Fair Value, Unvested balance Weighted Average Grant Date Fair Value, Unvested balance Schedule of Summarizes the Employee Warrant Activity [Abstract] Number of Warrants, Beginning balance Number of Warrants, Endning balance Outstanding and issued employee warrants Weighted Average Exercise Price Per Share, Beginning balance Weighted Average Exercise Price Per Share, Endning balance Aggregate Intrinsic Value, Beginning balance Aggregate Intrinsic Value, Endning balance Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants [Abstract] Stock-based compensation expense Schedule of Award Types of Company’s Stock-Based Compensation Expense [Abstract] Total Stock-based compensation expense Income Taxes [Abstract] Option Agreements [Abstract] Commitment and Contingencies [Abstract] Schedule of Company’s Supplemental Cash Flow Information Related to Leases [Abstract] Schedule of Company’s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract] Total undiscounted lease payments Total discounted lease payments Antidilutive Securities [Axis] Related Party Transactions [Abstract] Related Party Transaction [Axis] Assets Current assets: Cash and cash equivalents Subscription receivable Prepaid expenses and other current assets Property and equipment, net Operating lease right-of-use asset Operating lease right-of-use assets Other non-current assets Liabilities, Convertible Preferred Stock and Stockholders’ Equity Current liabilities: Accounts payable Operating lease liability, current Less: current portion of lease liability Related party common stock warrant liability Related party accounts payable and other current liabilities Operating lease liability, non-current Non-current portion of lease liability Operating lease liability, noncurrent Commitment and contingencies (Note 11) Convertible preferred stock convertible preferred stock, par value (in Dollars per share) convertible preferred stock, shares authorized convertible preferred stock, shares issued convertible preferred stock, shares outstanding convertible preferred stock, liquidation preference (in Dollars) Stockholders’ equity: Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively Carrying Value (in Dollars) Non-voting convertible preferred stock, par value (in Dollars per share) Non-voting convertible preferred stock, shares authorized Preferred Stock Authorized Non-voting convertible preferred stock, shares issued Shares issuable on conversion of Company preferred stock Non-voting convertible preferred stock, shares outstanding Common stock, $0.001 and $0.0001 par value as of September 30, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 34,998,550 and 3,197,975 shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively Common stock issued Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock shares (in Shares) Common stock, shares outstanding Additional paid-in capital Accumulated deficit Operating expenses Research and development Related party amount General and administrative Other income (expense) Interest income Net loss per share attributable to stockholders, basic (in Dollars per share) Loss per share – basic Net loss per share (in Dollars per share) Net loss per share attributable to stockholders, diluted (in Dollars per share) Loss per share – diluted Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in Shares) Weighted Average Shares Outstanding (in Shares) Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in Shares) Issuance of common stock Issuance of common stock (in Shares) Pre-funded warrants Issuance of Series A convertible preferred stock, net of issuance costs of $69 Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) Issuance of Series A Convertible Preferred Stock, Net of Issuance Costs Stock-based compensation expense Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares) Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares) Issuance costs of Pre-Closing Financing and reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares) Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares) Issuance cost of PIPE Financing Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Non-cash interest expense Non-cash lease expense Changes in operating assets and liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liability Related party accounts payable and other current liabilities Cash flows from investing activities: Cash flows from financing activities: Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid Gross proceeds (in Dollars) Proceeds from issuance of notes payable to related parties, net of issuance costs paid Proceeds from the Pre-Closing Financing, net Proceeds from the PIPE Financing, net Cash acquired in connection with the reverse recapitalization Supplemental disclosure of non-cash operating and financing activities: Operating lease liability arising from obtaining operating right-of-use asset Assets acquired in connection with the reverse recapitalization Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable PIPE Financing issuance costs included in accounts payable PIPE Financing issuance costs included in accrued expenses and other current liabilities Non-cash accrued interest on convertible note converted to common stock Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock Interest expense Prepaid expenses and other current assets Other non-current assets Purchases of property and equipment Other liabilities assumed in connection with the reverse recapitalization Related Party Related Party [Member] Series A convertible preferred stock Series A Series A Preferred Stock [Member] Series A non-voting convertible preferred stock Series A Non-Voting Series A Non-Voting Preferred Stock [Member] Series A Non-Voting Convertible Preferred Stock [Member] Series B Non-Voting Convertible Preferred Stock Series B Non-Voting Preferred Stock [Member] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Research and Development Expenses [Member] Series A Non-Voting Convertible Preferred Stockholders Series B Non-Voting Convertible Preferred Stockholders Convertible Preferred Stock Series B Non-Voting Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit Nature of the Business and Basis of Presentation Summary of Significant Accounting Policies Schedule of Property and Equipment Estimated useful life Reverse Recapitalization and Pre-Closing Financing Schedule of the Assets and Liabilities Cash and cash equivalents Other current assets